发明名称 INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
摘要 The invention provides indazole guanidine compounds that inhibit F1F0-ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
申请公布号 US2015152063(A1) 申请公布日期 2015.06.04
申请号 US201314403779 申请日期 2013.06.07
申请人 Lycera Corporation 发明人 Hurd Alexander R.;Skalitzky Donald J.;Taylor Clarke B.;Toogood Peter L.;Van Huis Chad A.
分类号 C07D231/56;C07D471/04;C07D413/12;C07D405/12;C07D401/12 主分类号 C07D231/56
代理机构 代理人
主权项 1. A compound represented by Formula I: including all stereoisomers, geometric isomers, and tautomers; or a pharmaceutically acceptable salt or solvate of any of the foregoing; wherein: A1 is one of the following: (i) phenyl or a six-membered heteroaryl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, cycloalkyl, heterocycloalkyl, hydroxyl, C1-C6alkoxy, cyano, —CO2R4, —C(O)R5, —S(O)R5, —SO2R5, —SO2N(R6)(R7), —C(O)N(R6)(R7), —N(R6)(R7), and —N(R4)C(O)(R5); or(ii)  that is optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, cycloalkyl, heterocycloalkyl, hydroxyl, and C1-C6alkoxy; wherein B1 is a 5-membered or 6-membered heterocycle; A2 is  wherein B2 is a 6-membered heteroaromatic group; R1 and R2 each represent independently hydrogen or alkyl; R3 is one of the following: (i) alkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of hydroxyl, alkoxyl, —O—(C(R4)2)m-alkoxyl, —O—(C(R4)2)m—OH, —N(R6)(R7), cycloalkyl, heterocycloalkyl, —N(R6)C(O)R8, —C(O)N(R6)(R7), —N(R6)C(O)N(R6)(R7), halogen, haloalkyl, and cyano;(ii) cycloalkyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, hydroxyl, cycloalkyl, hydroxyalkyl, alkoxy, —O—(C(R4)2)m-alkoxyl, —O—(C(R4)2)m—OH, and cyano; or(iii) heterocycloalkyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, hydroxyl, alkyl, cycloalkyl, hydroxyalkyl, alkoxy, —O—(C(R4)2)m-alkoxyl, —O—(C(R4)2)m—OH, and cyano; R4 represents independently for each occurrence hydrogen, alkyl, or cycloalkyl; or two occurrences of R4 attached to the same carbon atom are taken together with said carbon atom to form a saturated carbocylic ring; R5 represents independently for each occurrence alkyl or cycloalkyl; R6 and R7 each represent independently for each occurrence hydrogen, alkyl, or cycloalkyl; or R6 and R7 are taken together with the nitrogen atom to which they are attached to form a 3 to 7 membered heterocyclic ring optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, hydroxyl, alkyl, cycloalkyl, and C1-C6alkoxy; R8 is hydrogen, or R8 is alkyl substituted by hydroxyl, —N(H)(R6), heterocycloalkyl, —N(H)C(O)R10, —C(O)N(H)(R6), or —N(H)C(O)N(R6)(R7); R9 represents independently for each occurrence halogen, haloalkyl, alkyl, cycloalkyl, heterocycloalkyl, hydroxyl, C1-C6alkoxy, or cyano; R10 is alkyl, cycloalkyl, aryl, or aralkyl; and n is 0, 1, 2, 3, or 4; and m is 1, 2, 3, 4, or 5.
地址 Ann Arbor MI US